行情

TGTX

TGTX

TG Therapeutics
NASDAQ

实时行情|Nasdaq Last Sale

7.12
-0.56
-7.29%
盘后: 7.48 +0.36 +5.06% 19:44 12/06 EST
开盘
7.78
昨收
7.68
最高
8.00
最低
7.04
成交量
493.28万
成交额
--
52周最高
9.38
52周最低
3.320
市值
6.88亿
市盈率(TTM)
-3.2303
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

TGTX 新闻

  • TG Therapeutics Announces 100% Overall Response Rate in Relapsed/Refractory CLL Patients Treated With U2 (Umbralisib + Ublituximab) Plus Venetoclax at Cycle 7 (N=13) at ASH 2019
  • Benzinga.5小时前
  • TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition
  • GlobeNewswire.5小时前
  • The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
  • Benzinga.1天前
  • The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
  • Benzinga.1天前

更多

所属板块

生物技术和医学研究
+0.66%
制药与医学研究
+0.49%

热门股票

名称
价格
涨跌幅

TGTX 简况

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.
展开

Webull提供TG Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。